NASDAQ : AIFF
$0.02 (1.82%)
NASDAQ
Greg Lipschitz
Software - Application
Technology
AIFF
17
US
USD
0.00
1.82
1.78
1.27
0.00
$1.14M
11.74
2.29
-2.38
-0.48
-$1.82
-$19.88M
-565.40%
-565.09%
-94.68%
-82.09%
-1.75
-0.02
-0.02
1/5
0 Analysts
%
-12.85
2/9
$2.01M
$10.91M
$2.47M
-$8.91M
$15.13M
9.55
-1.74
1.82
-94.68%
-101.11%
-47.17%
-42.77%
-544 days
| Name | Title |
|---|---|
| Paul Krzywicki | Chief Financial Officer & Company Secretary |
| Gil Issachar | Head of AI & Neuroscience |
| David DeCaprio | President, Chief Operating Officer & Director |
| Greg Lipschitz | Chief Executive Officer & Director |
No votes yet today — be the first to share your view!
About Firefly Neuroscience, Inc. (NASDAQ:AIFF) Stock
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners. ...
2026-07-28 07:50:00
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
2026-06-02 07:40:00
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (“PTSD”) using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (“TBI”).
Frequently Asked Questions
What is the current Firefly Neuroscience, Inc. (AIFF) stock price?
Firefly Neuroscience, Inc.(NASDAQ:AIFF) stock price is $1.1913 in the last trading session. During the trading session, AIFF stock reached the peak price of $3.63 while $0.62 was the lowest point it dropped to. The percentage change in AIFF stock occurred in the recent session was 1.82% while the dollar amount for the price change in AIFF stock was $0.02.
AIFF's industry and sector of operation?
The NASDAQ listed AIFF is part of Software - Application industry that operates in the broader Technology sector.
Who are the executives of AIFF?
Paul Krzywicki
| Chief Financial Officer & Company Secretary
Gil Issachar
| Head of AI & Neuroscience
David DeCaprio
| President, Chief Operating Officer & Director
Greg Lipschitz
| Chief Executive Officer & Director
|
How many employees does AIFF have?
Number of AIFF employees currently stands at 17. AIFF operates from 1100 Military Road, Kenmore, NY 14217, US.
Link for AIFF official website?
Official Website of AIFF is: https://fireflyneuro.com
How do I contact AIFF?
AIFF could be contacted at phone #888-237-6412 and can also be accessed through its website. AIFF operates from 1100 Military Road, Kenmore, NY 14217, US.
How many shares of AIFF are traded daily?
The average number of AIFF shares traded daily for last 3 months was 230.58K.
What is the market cap of AIFF currently?
The market value of AIFF currently stands at $18.59M with its latest stock price at $1.1913